Unlike other types of cancer, which are silent and asymptomatic, ovarian cancer may produce very serious signs and symptoms even at a very early stage. Some of the most common symptoms of ovarian cancer can be very similar to less serious conditions such as urinary tract infections or mild abdominal problems. These symptoms include:
What is Ovarian Cancer?
varian cancer occurs when some cells in your ovaries start to rapidly divide uncontrollably, creating growths or tumors around the ovaries and surrounding tissues. According to the American Cancer Association, ovarian cancer is the fifth most common type of cancer among women, and it is estimated that more than 20,000 women will be diagnosed with this type of cancer every year.
Ovarian cancer affects the ovaries, which are a keypart of the female reproductive system. All females have two ovaries, each about the size of an almond, which lie on either side of the uterus and are responsible for creating and releasing eggs during the menstrual cycle, as well as producing the two mean female sex hormones: estrogen and progesterone.
How is Ovarian Cancer Diagnosed?
- Indigestion and changes in appetite
- Changes in bowel movements
- Urinary incontinence or increased urge to urinate
- Pain around the pelvis area
- Back pain
When ovarian cancer is found at its early stages, patients have nearly a 95% chance of living more than five years after their diagnosis. However, only 20% of ovarian cancer cases are found early.
Currently, there are no tests to specifically diagnose ovarian cancer. This type of cancer is usually found during routine checkups when a professional perform a pelvic exam to evaluate the shape, size and any abnormalities in around the uterus and ovaries.
Unfortunately, it is very hard to feel or see any to see or feel any tumors early, which is why most women are diagnosed later. In addition to a pelvic exam, doctors might order a transvaginal ultrasound or a CA-125 blood test.
What Causes Ovarian Cancer?
Scientists still aren’t exactly sure about what causes ovarian cancer. As with many other types of cancer, there are a number of risk factors that can increase the likelihood of a woman to develop this kind of cancer, however, have one or even a few of these risk factors doesn’t mean that a person is destined to develop the disease.
These are some risk factors that have been observed in women with ovarian cancer:
Older women seem to be more likely than younger women to develop ovarian cancer. In fact, most women with ovarian cancer have been diagnosed after menopause, and half of all ovarian cancers are diagnosed in women 60 and older.
Researchers have observed that women who continue taking hormones after menopause has ended have a higher risk of developing ovarian cancer. Additionally, women who have taken estrogen without progesterone for more than five years also have an increased risk of developing ovarian cancer.
Women with a family history of ovarian cancer (mother, sisters, grandmothers, aunts, etc.) have a higher risk of developing it than those who do not have any family history of ovarian cancer.
Having a high body mass index (BMI) has been linked to several types of cancer, including ovarian cancer. However, researchers are still trying to figure out the relationship between cancer cells and obesity.
Women who have had at least one successful pregnancy before the age of 30 seem to have a decreased risk of developing ovarian cancer, which also appears to decline with the number of children the woman has. On the other hand, women who never had children or had their first child later in life have an increased risk of developing ovarian cancer.
How is Ovarian Cancer Treated?
The treatment course for ovarian cancer depends on the stage the cancer is in. Cancer is categorized in stages in order to describe its size and severity. The stages are as follows:
Depending on which stage the ovarian cancer is found, the doctor and the patient may decide in one – or several treatments to attack cancer cells. Some common ovarian cancer treatments include:
- Hormone therapy
- Clinical trials
Ovarian Cancer Clinical Trials
Clinical trials have contributed a lot to the current survival rates of ovarian cancer. However, researchers are still trying to find better screening methods that will allow doctors to find and diagnose ovarian cancer earlier, thus improving the patient’s life expectancy. Scientists are continuously researching new, less invasive treatment options that might potentially cure ovarian cancer.
If you are interested in participating in a clinical trial, ask your doctor or contact your local hospital and/or university to find out which trials are recruiting volunteers near you.
ClinicalTrials.gov: Recruiting Studies | Ovarian Cancer | Last update posted in the last 300 days Studies found on ClinicalTrials.gov by a search of: Recruiting Studies | Ovarian Cancer | Last update posted in the last 300 days
First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b
on May 20, 2020 at 4:00 pm
Conditions: Ovarian Cancer; Nonsmall Cell Lung CancerIntervention: Biological: XMT-1592Sponsors: Mersana Therapeutics; IQVIA BiotechRecruiting
Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer
on May 6, 2020 at 4:00 pm
Condition: Platinum-resistant Ovarian CancerInterventions: Drug: Niraparib; Drug: AnlotinibSponsor: Jihong LiuRecruiting
Register to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Patients in Austria
on April 30, 2020 at 4:00 pm
Condition: Recurrent Ovarian CarcinomaIntervention: Sponsor: Medical University InnsbruckRecruiting
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
on April 21, 2020 at 4:00 pm
Conditions: Advanced Cancer; Ovarian Cancer; Lung Cancer; Colon Cancer; Plasma Cell Neoplasm; Breast CancerIntervention: Drug: COM902Sponsor: Compugen LtdRecruiting
Impact of the COVID-19 Pandemic in Gynecological Oncology
on April 17, 2020 at 4:00 pm
Conditions: Gynecologic Cancer; Breast Neoplasm Female; Uterine Neoplasms; Ovarian Neoplasms; Uterine Cervical Neoplasms; Vulvar Neoplasms; Vaginal NeoplasmsIntervention: Other: modification of the planned therapeutic managementSponsor: Hospices Civils de LyonRecruiting
Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer
on April 15, 2020 at 4:00 pm
Condition: Platinum-resistant Recurrent Ovarian CancerInterventions: Drug: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd; Drug: PLD 40mg/m2 ivgtt q4wSponsors: Chinese Academy of Medical Sciences; Jiangsu HengRui Medicine Co., Ltd.Recruiting
Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum—Partial Sensitive Recurrent Ovarian Cancer
on April 8, 2020 at 4:00 pm
Condition: Ovarian CancerInterventions: Drug: Doxorubicin Hydrochloride Liposome Injection+carboplatin; Drug: paclitaxel +carboplatinSponsor: Hunan Cancer HospitalRecruiting
Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin Chemotherapy
on March 17, 2020 at 4:00 pm
Condition: Ovarian CarcinomaInterventions: Dietary Supplement: Dietary Intervention; Other: Media Intervention; Behavioral: Telephone-Based InterventionSponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)Recruiting
A Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
on March 5, 2020 at 5:00 pm
Conditions: Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube CancerIntervention: Drug: Mirvetuximab SoravtansineSponsors: ImmunoGen, Inc.; IQVIA BiotechRecruiting
Study of AMG 650 in Adult Participants With Advanced Solid Tumors
on March 3, 2020 at 5:00 pm
Condition: Advanced Solid TumorsIntervention: Drug: AMG 650Sponsor: AmgenRecruiting
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
on March 2, 2020 at 5:00 pm
Conditions: Endometrial Cancer; Endometrioid Adenocarcinoma; Endometrial Cancer Stage IIntervention: Other: Physical examSponsor: Memorial Sloan Kettering Cancer CenterRecruiting
Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE)
on February 28, 2020 at 5:00 pm
Condition: Breast Neoplasm Malignant FemaleInterventions: Drug: Letrozole; Other: standard-stimulated cohortSponsors: Erasme University Hospital; University Hospital, LilleRecruiting
- Key Statistics for Ovarian Cancer. American Cancer Society (April 11, 2018). Recovered from: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html